MTOR and cancer: The GSVA revealed that the low-risk group exhibited enriched immune-related pathways (such as the IL6-JAK-STAT3 signaling and inflammatory response pathways), while the high-risk group exhibited enriched cancer-related pathways (such as PI3K-AKT-MTOR signaling and G2M checkpoint pathways) (Fig. 6A).